| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 18.44% | Argus Research | → $53 | Initiates Coverage On | → Buy |
| 05/18/2023 | 78.77% | Stephens & Co. | → $80 | Reiterates | Overweight → Overweight |
| 05/18/2023 | 101.12% | Baird | $78 → $90 | Maintains | Outperform |
| 05/01/2023 | — | Northcoast Research | Downgrades | Buy → Neutral | |
| 02/22/2023 | 74.3% | Baird | $74 → $78 | Maintains | Outperform |
| 02/22/2023 | 83.24% | Guggenheim | $75 → $82 | Maintains | Buy |
| 02/21/2023 | 74.3% | Stephens & Co. | → $78 | Reiterates | → Overweight |
| 11/18/2022 | 65.36% | Stephens & Co. | $72 → $74 | Maintains | Overweight |
| 05/20/2022 | 224.02% | Stephens & Co. | $140 → $145 | Maintains | Overweight |
| 05/21/2021 | 224.02% | Truist Securities | $135 → $145 | Maintains | Buy |
| 02/12/2021 | 212.85% | Stephens & Co. | $122 → $140 | Upgrades | Equal-Weight → Overweight |
| 02/05/2021 | — | Northcoast Research | Upgrades | Neutral → Buy | |
| 09/04/2020 | 161.45% | Truist Securities | $110 → $117 | Maintains | Buy |
| 05/22/2020 | 123.46% | Jefferies | $84 → $100 | Maintains | Buy |
| 05/21/2020 | 89.94% | CFRA | $90 → $85 | Maintains | Hold |
| 05/18/2020 | 101.12% | SunTrust Robinson Humphrey | $110 → $90 | Maintains | Buy |
| 04/23/2020 | 45.25% | JP Morgan | → $65 | Upgrades | Underweight → Neutral |
| 04/16/2020 | 63.13% | Stephens & Co. | $95 → $73 | Maintains | Equal-Weight |
| 04/09/2020 | — | Jefferies | Upgrades | Hold → Buy | |
| 03/19/2020 | 78.77% | Baird | $90 → $80 | Maintains | Outperform |
| 03/11/2020 | 101.12% | Baird | $100 → $90 | Maintains | Outperform |
| 02/21/2020 | 145.81% | SunTrust Robinson Humphrey | $100 → $110 | Maintains | Buy |
| 02/21/2020 | 123.46% | Baird | $96 → $100 | Maintains | Outperform |
| 11/22/2019 | 123.46% | SunTrust Robinson Humphrey | $92 → $100 | Maintains | Buy |
| 10/18/2019 | — | Guggenheim | Upgrades | Neutral → Buy | |
| 09/06/2019 | 58.66% | JP Morgan | $62 → $71 | Maintains | Underweight |
| 05/17/2019 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/21/2018 | 5.03% | JP Morgan | $48 → $47 | Downgrades | Neutral → Underweight |
| 09/20/2018 | — | Gabelli & Co. | Upgrades | Hold → Buy |
What is the target price for Copart (CPRT)?
The latest price target for Copart (NASDAQ: CPRT) was reported by Argus Research on September 8, 2023. The analyst firm set a price target for $53.00 expecting CPRT to rise to within 12 months (a possible 18.44% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Copart (CPRT)?
The latest analyst rating for Copart (NASDAQ: CPRT) was provided by Argus Research, and Copart initiated their buy rating.
When is the next analyst rating going to be posted or updated for Copart (CPRT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Copart, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Copart was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
Is the Analyst Rating Copart (CPRT) correct?
While ratings are subjective and will change, the latest Copart (CPRT) rating was a initiated with a price target of $0.00 to $53.00. The current price Copart (CPRT) is trading at is $44.75, which is within the analyst's predicted range.